Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDiclofenac sodium salt is a nonsteroidal, anti-inflammatory drug (NSAID); inhibits COX-1 and COX-2 (IC50 values are 0.075 μM for COX-1 and 0.038 μM for COX-2 in human whole blood assay).
M. Wt | 318.13 |
Formula | C14H10Cl2NNaO2 |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 15307-79-6 |
PubChem ID | 5018304 |
InChI Key | KPHWPUGNDIVLNH-UHFFFAOYSA-M |
Smiles | [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 15.91 | 50 | |
DMSO | 31.81 | 100 |
The following data is based on the product molecular weight 318.13. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.14 mL | 15.72 mL | 31.43 mL |
5 mM | 0.63 mL | 3.14 mL | 6.29 mL |
10 mM | 0.31 mL | 1.57 mL | 3.14 mL |
50 mM | 0.06 mL | 0.31 mL | 0.63 mL |
References are publications that support the biological activity of the product.
Warner et al (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc.Natl.Acad.Sci.USA 96 7563 PMID: 10377455
Bort et al (1998) Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J.Pharmacol.Exp.Ther. 288 65 PMID: 9862754
Laneuville et al (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J.Pharmacol.Exp.Ther. 271 927 PMID: 7965814
If you know of a relevant reference for Diclofenac sodium salt, please let us know.
Keywords: Diclofenac sodium salt, Diclofenac sodium salt supplier, nsaids, non-steroidal, anti-inflammatories, anti-inflammatory, cox-1, cox-2, cyclooxygenase, inhibitors, inhibits, Cyclooxygenase, 4454, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Diclofenac sodium salt. Do you know of a great paper that uses Diclofenac sodium salt from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Diclofenac sodium salt and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.